Acesis Biomed

Executive Summary

Acesis Biomed is a private biomedical company headquartered in London, UK, with operations in Colorado, USA, focused on developing an oral drug delivery platform for metabolic and endocrine disorders. Founded in 2018, the company's lead program targets male hypogonadism (low testosterone), aiming to provide a non-invasive oral alternative to current injectable or topical therapies. The platform leverages novel formulation technologies to enhance oral bioavailability of peptide and small-molecule drugs, potentially addressing significant unmet needs in patient convenience and compliance. Acesis Biomed's approach could disrupt the large and growing testosterone replacement therapy market, which is valued at over $2 billion annually. However, as a preclinical-stage company, it has not yet disclosed total funding, valuation, or pipeline details publicly, limiting visibility. The company is positioned at the intersection of drug delivery innovation and endocrine disease, with potential expansion into other metabolic conditions such as diabetes or obesity.

Upcoming Catalysts (preview)

• Q4 2026Completion of preclinical proof-of-concept studies for lead oral testosterone candidate60% success
• Q2 2027IND/CTA filing for first-in-human trials40% success
• Q3 2026Series A financing round or strategic partnership for platform development50% success